Sterile Drug Product Container Packaging in Pharmaceuticals: Types, Materials, Advantages & Disadvantages
Sterile packaging of pharmaceutical products is not just a regulatory requirement; it is a life-saving discipline. From injectable biologics to implantable medical devices, packaging is often the final barrier that keeps a sterile product safe from contamination on its way to the patient. Choosing the correct packaging system matters as much as the drug formulation itself. A failure in packaging, whether due to material selection, sealing, or integrity loss in transit, can render a perfectly manufactured medicine unsafe.
What Makes Packaging of Pharmaceutical products “Sterile”?
Sterile packaging is engineered and validated to maintain sterility from the point of manufacture through storage, transport, and eventual patient use. Systems must withstand sterilization methods (steam, gamma, e-beam, ETO) without compromising material integrity, extractables/leachables profile, or barrier function.
Common Types of Pharmaceutical Product Packaging
Vials (Glass or Polymer)
- Used widely for small-volume parenterals, sterile powders, and lyophilized biologics.
- Often paired with rubber stoppers and aluminum crimp seals.

Pre-filled Syringes (Glass or Polymer)
- Growing in popularity due to convenience, dose accuracy, and reduced needle manipulation.
- Used for biologics, vaccines, and high-value specialty drugs.

Cartridges
- Used in autoinjectors, wearable pumps, and pen injectors for chronic care therapies (insulins, GLP-1s, etc.)

IV Bags (PVC or Non-PVC Films)
- Large-volume parenterals such as saline, nutrition, and antibiotics.
- Shift from PVC to polypropylene/ethylene-vinyl-acetate due to concerns about DEHP leaching.

The following are some of the plastics that have replaced PVC
- Polyolefins (Polypropylene-based films)
- EVA (Ethylene-Vinyl Acetate)
- Multilayer laminates using PP/PE/EVOH combinations
- Cyclic olefin polymers (in specialty applications)
Ampoules (Glass)
- Mature technology primarily for small-volume injectables with long-term stability.

Materials Used and Why They Matter
Sterile materials for pharmaceutical product packaging must meet a high bar: barrier properties, machinability, chemical compatibility, leachable profile, and sterilization stability. Common classes include:
Type I Glass (Borosilicate)
Gold standard for parenterals due to chemical resistance.
COP/Cyclic Olefin Polymer
Break-resistant, low-protein adsorption, lighter, friendly to large biologics.
Rubber Elastomers (bromobutyl, chlorobutyl)
Stopper materials for vials and syringe plungers.
- Butyl Rubber: Bromobutyl & Chlorobutyl which has become the Industry standard for vials and prefilled syringes. They have an excellent gas/moisture barrier, and low extractables.
- Natural Rubber: Rare today in injectables due to allergy/latex sensitivity risk. Historically used in some older vial stoppers.
- EPDM (Ethylene-Propylene-Diene Monomer): Excellent chemical resistance, no halogens, good steam resistance. Used where butyl compatibility is an issue.
- Silicone Rubber (Q-Rubber): Used mainly in plunger tips, septa, and devices. High thermal stability but higher permeability vs. butyl.
- Fluoroelastomers (FKM, e.g., Viton® coatings): Used more as barrier coatings on butyl cores. Resists aggressive solvents and minimizes extractables/leachables.
- TPE/TPV Compounds (Thermoplastic Elastomers): Emerging use in some device closures and combination products. Moldable like plastics, good dimensional stability, low particulates.
Aluminum
Provides tamper evidence and mechanical closure.
Multilayer Films (PP, EVA, PE)
Used in IV bags and sterile device packaging.
Advantages & Disadvantages of different container types
| System | Advantages | Disadvantages |
| Ampoules | Hermetic seal; no elastomer contact | Glass particulates risk when opened; needs breaking |
| Glass Vials | Inert, excellent barrier, long track record as top choice for packaging of pharmaceutical products | Fragile; delamination risk; needs secondary closure |
| Pre-filled Syringes | Convenience, lower prep errors, less waste | Higher cost; plunger interaction; silicone oil concerns |
| COP Polymer Vials/Syringes | Shatterproof; good with biologics; lightweight | Heat sensitivity; narrower regulatory familiarity |
| Blow-Fill-Seal (BFS) | Closed advanced aseptic process; incredibly low contamination risk; high throughput; no glass breakage; cost-effective at scale | Limited to polymers; weaker barrier vs. glass; heat exposure to product; high capital cost; less suited for sensitive biologics; user resistance to change to BFS vials |
| IV Bags (Non-PVC) | No plasticizer risk; flexible | Can be light/oxygen sensitive; weld seam integrity limits |
Why Selection Has Become More Strategic
One of the reasons that packaging of pharmaceutical products is important today is that the modern biologics and cell/gene therapies are more fragile than traditional small molecules. They are sensitive to siliconization, shear, oxygen ingress, pH shifts, and even the micro-interactions with elastomers or lubricants. That is why polymers like COP are increasingly considered for high-value products, even though glass still dominates overall.
In parallel, patient-centric delivery (pens, on-body injectors, autoinjectors) demands sterile packaging that integrates with a delivery device while maintaining integrity under handling stress. This shifts the design conversation upstream, where packaging is part of the therapy experience, not an afterthought.
Regulatory Expectations & Risk Considerations
Regulators expect firms to demonstrate:
- Container-closure integrity through the life of the product.
- Compatibility and Extractable Leachable profiles
- Validated sterilization and aseptic processing controls
- Distribution robustness (vibration, altitude, temperature excursions)
- Microbial ingress prevention
Failures are expensive: recalls for cracked vials, particulate contamination, or compromised seals not only cost millions but also erode trust and jeopardize patient safety.
Final Thought
Sterile product packaging is where engineering rigor, regulatory science, and patient safety converge. The “best” system is never one-size-fits-all, and it is the one that balances sterility, compatibility, manufacturability, and real-world use. As therapeutics evolve, so too must the materials and thinking that protect them.
Martin Van Trieste is an accomplished entrepreneur, board governance expert, executive coach and biopharmaceutical executive. Martin is the retired founder and President Emeritus of Civica Rx, and was previously Amgen’s Chief Quality Officer.
He also serves on the board for Redica Systems. In 2023, SmartSkin was honoured to welcome Martin Van Trieste as Chair of its Board of Directors. Throughout his career, Martin has been passionate about serving patients, changing quality cultures, quality improvement and compliance initiatives in complex biotechnology, pharmaceutical and medical device manufacturing environments.

How SmartSkin helped eliminate quality investigations and cut vial defects by 70%.
Download this free case study to learn how a leading manufacturer reduced vial defects by 70% using SmartSkin Technologies Digital Container Twins solutions.